Heron Therapeutics, Inc. (HRTX): Price and Financial Metrics


Heron Therapeutics, Inc. (HRTX): $8.15

0.04 (+0.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 450

in industry

HRTX POWR Grades


  • HRTX scores best on the Growth dimension, with a Growth rank ahead of 75.73% of US stocks.
  • HRTX's strongest trending metric is Sentiment; it's been moving up over the last 170 days.
  • HRTX ranks lowest in Quality; there it ranks in the 5th percentile.

HRTX Stock Summary

  • Heron Therapeutics Inc's stock had its IPO on August 27, 1987, making it an older stock than 91.46% of US equities in our set.
  • With a year-over-year growth in debt of 562.05%, Heron Therapeutics Inc's debt growth rate surpasses 97.71% of about US stocks.
  • As for revenue growth, note that HRTX's revenue has grown -16.31% over the past 12 months; that beats the revenue growth of just 10.52% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Heron Therapeutics Inc are MNOV, BLI, ADVM, CCXI, and FREQ.
  • Visit HRTX's SEC page to see the company's official filings. To visit the company's web site, go to www.herontx.com.

HRTX Valuation Summary

  • In comparison to the median Healthcare stock, HRTX's price/earnings ratio is 113.97% lower, now standing at -5.1.
  • Over the past 243 months, HRTX's EV/EBIT ratio has gone down 11.1.
  • Over the past 243 months, HRTX's EV/EBIT ratio has gone down 11.1.

Below are key valuation metrics over time for HRTX.

Stock Date P/S P/B P/E EV/EBIT
HRTX 2021-08-31 14.3 7.4 -5.1 -4.9
HRTX 2021-08-30 14.3 7.4 -5.1 -4.9
HRTX 2021-08-27 14.2 7.4 -5.0 -4.9
HRTX 2021-08-26 14.1 7.3 -5.0 -4.8
HRTX 2021-08-25 14.3 7.4 -5.1 -4.9
HRTX 2021-08-24 14.1 7.3 -5.0 -4.9

HRTX Growth Metrics

    The 5 year cash and equivalents growth rate now stands at 51.85%.
  • The 4 year cash and equivalents growth rate now stands at 51.85%.
  • Its 3 year net income to common stockholders growth rate is now at -71.62%.
HRTX's revenue has moved down $39,479,000 over the prior 15 months.

The table below shows HRTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 86.296 -210.65 -228.318
2021-06-30 83.031 -199.538 -234.138
2021-03-31 83.256 -193.823 -228.313
2020-12-31 88.638 -184.82 -227.278
2020-09-30 103.116 -159.243 -222.917
2020-06-30 125.775 -142.66 -198.284

HRTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HRTX has a Quality Grade of D, ranking ahead of 9.05% of graded US stocks.
  • HRTX's asset turnover comes in at 0.243 -- ranking 181st of 682 Pharmaceutical Products stocks.
  • IBIO, COLL, and PTGX are the stocks whose asset turnover ratios are most correlated with HRTX.

The table below shows HRTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.243 0.485 -0.993
2021-06-30 0.228 0.515 -1.093
2021-03-31 0.224 0.582 -1.080
2020-12-31 0.214 0.592 -0.933
2020-09-30 0.227 0.586 -0.779
2020-06-30 0.277 0.581 -0.676

HRTX Price Target

For more insight on analysts targets of HRTX, see our HRTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $33.00 Average Broker Recommendation 1.42 (Moderate Buy)

HRTX Stock Price Chart Interactive Chart >

Price chart for HRTX

HRTX Price/Volume Stats

Current price $8.15 52-week high $20.45
Prev. close $8.11 52-week low $7.79
Day low $7.79 Volume 2,386,800
Day high $8.29 Avg. volume 1,995,716
50-day MA $9.17 Dividend yield N/A
200-day MA $12.15 Market Cap 830.77M

Heron Therapeutics, Inc. (HRTX) Company Bio


Heron Therapeutics is a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs. The company was founded in 1983 and is based in Redwood City, CA.


HRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

HRTX Latest Social Stream


Loading social stream, please wait...

View Full HRTX Social Stream

Latest HRTX News From Around the Web

Below are the latest news stories about Heron Therapeutics Inc that investors may wish to consider to help them evaluate HRTX as an investment opportunity.

Newbridge Financial Services Group, Inc. Buys Apple Inc, NVIDIA Corp, NXP Semiconductors NV, ...

Investment company Newbridge Financial Services Group, Inc. (Current Portfolio) buys Apple Inc, NVIDIA Corp, NXP Semiconductors NV, Microsoft Corp, Tesla Inc, sells NIO Inc, Lemonade Inc, Alibaba Group Holding, Carnival Corp, Blackstone Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Newbridge Financial Services Group, Inc..

Yahoo | January 19, 2022

Jefferies Thinks Heron Therapeutics’ Stock is Going to Recover

Jefferies analyst Kelly Shi maintained a Buy rating on Heron Therapeutics (HRTX – Research Report) today and set a price target of $23.00. The company's shares closed last Friday at $8.70, close to its 52-week low of $8.09. According to TipRanks.com, Shi 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -19.9% and a 17.9% success rate. Shi covers the Healthcare sector, focusing on stocks such as Bicycle Therapeutics, Legend Biotech, and ImmunoGen. Currently, the analyst consensus on Heron Therapeutics is a Strong Buy with an average price target of $35.67.

Howard Kim on TipRanks | January 18, 2022

Private Asset Management Inc Buys ASML Holding NV, Public Storage, Palantir Technologies Inc, ...

San Diego, CA, based Investment company Private Asset Management Inc (Current Portfolio) buys ASML Holding NV, Public Storage, Palantir Technologies Inc, Kimco Realty Corp, Vanguard Dividend Appreciation FTF, sells Alibaba Group Holding, Heron Therapeutics Inc, The Energy Select Sector SPDR Fund, Danaher Corp, Dominion Energy Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Private Asset Management Inc.

Yahoo | January 4, 2022

Heron Therapeutics Inc. (HRTX) Recovers 19.27% From Low: Are We There Yet?

Heron Therapeutics Inc. (NASDAQ:HRTX) concluded the trading at $9.81 on Wednesday, December 22 with a rise of 1.55% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $9.66 and 5Y monthly beta was reading 1.38 with its price kept floating in the Heron Therapeutics Inc. (HRTX) Recovers 19.27% From Low: Are We There Yet? Read More »

Stocks Register | December 23, 2021

Heron Therapeutics Inc. (HRTX) Is Becoming Less Appealing To Investors After A -1.23% Fall

Heron Therapeutics Inc. (NASDAQ:HRTX) has a beta value of 1.35 and has seen 1.07 million shares traded in the last trading session. The company, currently valued at $915.38M, closed the last trade at $9.66 per share which meant it lost -$0.12 on the day or -1.23% during that session. The HRTX stock price is -131.88% Heron Therapeutics Inc. (HRTX) Is Becoming Less Appealing To Investors After A -1.23% Fall Read More »

Marketing Sentinel | December 22, 2021

Read More 'HRTX' Stories Here

HRTX Price Returns

1-mo -12.46%
3-mo -25.98%
6-mo -34.06%
1-year -53.05%
3-year -69.79%
5-year -35.06%
YTD -10.73%
2021 -56.86%
2020 -9.94%
2019 -9.41%
2018 43.31%
2017 38.17%

Continue Researching HRTX

Here are a few links from around the web to help you further your research on Heron Therapeutics Inc's stock as an investment opportunity:

Heron Therapeutics Inc (HRTX) Stock Price | Nasdaq
Heron Therapeutics Inc (HRTX) Stock Quote, History and News - Yahoo Finance
Heron Therapeutics Inc (HRTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9865 seconds.